Published Date: 08 Mar 2023
A group of scientists led by Dr. Yamin Zhang and Dr. Colin Franz of Shirley Ryan AbilityLab and Dr. John Rogers of Northwestern University have developed a new technique. Change...
Read Full NewsThe rheumatology year in review highlights FDA approvals and pivotal data readouts.
Johnson & Johnson plans to initiate a phase 3 study based off the positive data.
Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.
Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.
The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.
Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101
Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression
1.
Trump slashed US cancer research by 31 percent: Senate report
2.
A Texas study found that the majority of pancreatic cancer patients do not receive life-saving surgery.
3.
The majority of cancer medications that receive expedited approval end up failing confirmatory trials.
4.
An ancient signaling pathway and 20 years of research offer hope for rare cancer
5.
Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain
1.
Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies
2.
Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology
3.
Uncovering the Mysteries of Breast Cancer: The Journey to a Cure
4.
Breaking Down Amyloidosis: Understanding the Disease
5.
Liquid Biopsy in Oncology: Innovations in Cancer Detection, Monitoring, and Clinical Use
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
2.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
Navigating the Complexities of Ph Negative ALL - Part XIII
5.
Navigating the Complexities of Ph Negative ALL - Part XV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation